By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

NovaBay Pharmaceuticals, Inc. 

5980 Horton Street
Suite 550
Emeryville  California  94608  U.S.A.
Phone: 510-899-8800 Fax: 510-779-5468


SEARCH JOBS
NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products: Aganocide® compounds and NeutroPhase®. Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay’s clinical development activities are focused on three disease areas: Dermatology, Ophthalmology and Urology.

NovaBay has entered into a licensing and research collaboration agreement with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology. NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. NovaBay believes that NeutroPhase is the only patented pure hypochlorous acid solution available which has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.


Key Statistics


Email: employment@novabaypharma.com
Ownership: Public

Web Site: NovaBay
Employees:
Symbol: NBY
 









Company News
NovaBay (NBY) Reports 2016 Second Quarter Financial Results 8/12/2016 9:08:55 AM
NovaBay (NBY) To Hold Second Quarter 2016 Conference Call On August 11 8/4/2016 12:08:57 PM
NovaBay (NBY) Completes $11.8 Million Private Placement 8/2/2016 11:49:00 AM
Bay Area's NovaBay (NBY) Names Mark Sieczkarek as Permanent CEO 6/13/2016 6:06:06 AM
NovaBay (NBY) Reports 2016 First Quarter Financial Results 5/13/2016 9:39:26 AM
NovaBay (NBY) Appoints Todd Zavodnick To Its Board Of Directors 5/10/2016 12:13:04 PM
NovaBay (NBY) To Hold First Quarter 2016 Conference Call On May 12 5/5/2016 10:52:28 AM
Clinical Data Presented At Association for Research in Vision & Ophthalmology Showing NovaBay (NBY)’s Avenova Reduces Bacteria On Ocular Skin Surface By More Than 90% 5/3/2016 9:26:55 AM
NovaBay (NBY) Announces Agreement For Nearly $12 Million In Two-Tranche Private Placement 4/6/2016 9:13:03 AM
NovaBay (NBY) Announces Filing Of Annual Report On Form 10-K 3/22/2016 10:13:21 AM
12345678910...
//-->